Introduction {#sec1}
============

Sweat gland carcinomas are extremely rare tumors. The age-adjusted incidence rate of cutaneous appendageal carcinomas, including sweat gland carcinomas, is 5.1 per 1 million person-years.[@bib1] The main treatment method is wide local excision and lymph node dissection, and chemotherapy and radiation therapy have limited roles.[@bib2]

Syringomatous carcinoma is a rare malignant skin appendageal tumor that arises from the sweat glands.[@bib3] Syringomatous carcinoma occurs as a slow growing, locally destructive, firm, and poorly demarcated nodule or plaque and is located predominantly on the face or scalp.[@bib4] In this report, we describe the case of a patient with syringomatous carcinoma of the face who received intensity modulated radiation therapy (IMRT). The patient provided written consent to report the details of her case, including images.

Case Report {#sec2}
===========

The patient was a 79-year-old Japanese woman. In 2006, she noticed a hardening of the skin on both cheeks. In February 2015, her entire face began to swell. The swelling progressively worsened, until April 2015 when the patient had difficulty to open her eyes. With these complaints, she visited our hospital in June 2016.

On physical examination, she presented with board-like induration of the face, which extended from the cheek on either side to the nose ([Fig 1](#fig1){ref-type="fig"}). A head and neck magnetic resonance imaging scan revealed a subcutaneous mass with contrast enhancement that extended from both cheeks to the nose ([Fig 2](#fig2){ref-type="fig"}). A histopathologic examination of skin biopsy specimens of the left cheek revealed evidence of adenocarcinoma that extended from the subcutaneous fat layer to the facial muscles. Some clear 2-layer structures like sweat ducts were observed ([Fig 3](#fig3){ref-type="fig"}). Based on these findings, the tumor was diagnosed as syringomatous carcinoma. The tumor infiltrated the superficial facial muscles and was classified per the TNM classification system of skin cancer (Union for International Cancer Control, 8^th^ edition, 2017) as T3N0M0. Radiation therapy was selected as a treatment because surgery would have necessitated excisions of wide areas of the face.Figure 1Clinical photograph of the patient (June 2016).Figure 2Magnetic resonance imaging scan of the tumor (April 2016, contrast-enhanced T1-weighted images with fat suppression). (A) Sagittal and (B-D) axial views.Figure 3Photomicrograph of the tumor cells (hematoxylin and eosin stain).

In the radiation therapy planning, the patient\'s eyeballs, lenses, optic nerves, optic chiasma, oral cavity, brain, brainstem, spinal cord, middle ears, and mandible were contoured as organs at risk (OARs). The gross tumor volume was defined as the macroscopic tumor detected on computed tomography and magnetic resonance imaging scans. A margin of 2 cm was drawn around the gross tumor volume to define the clinical target volume. The planning target volume was defined by addition of a margin of 5 mm to the clinical target volume ([Fig 4](#fig4){ref-type="fig"}A). IMRT was delivered with seven intensity modulated beams of 6 MV photons ([Fig 4](#fig4){ref-type="fig"}B). A 1 cm bolus was used throughout the entire treatment to ensure sufficient subcutaneous doses to the subcutaneous tissues, and a total dose of 60 Gy in 30 fractions was prescribed to the median of the planning target volume. The dose distribution chart is shown in [Figure 4](#fig4){ref-type="fig"}C through F. For dose prescription, we considered the tolerance doses of each OAR. The D~mean~ of the left lens was 35.3 Gy, which was higher than dose constraints of 10 Gy. The doses to all other OARs were within the respective dose constraints.Figure 4Details of radiation therapy. (A) Contouring (red line: gross tumor volume; orange line: clinical target volume; yellow line: planning target volume), (B) layout of the 7 photon beams, and (C-F) dose distribution of the photon intensity modulated radiation therapy (red line:100% = 60 Gy; orange line: 90%; yellow line: 80%; green line: 70%; light blue line: 60%; blue line: 50%).

A month after completion of the radiation therapy, the facial swelling disappeared and the patient was able to open her eyes again without difficulty. Her activities of daily living improved, and she was able to enjoy her hobby of field work, which she had been unable to do before treatment.

The acute adverse events were oral mucositis (grade 2; Common Terminology Criteria for Adverse Events, version 5.0), cheilitis (grade 2), oral pain (grade 2), and radiation dermatitis (grade 2). The late adverse events were periodontal disease (grade 3), left cataract (grade 2), transient left periorbital edema (grade 1), and telangiectasia, especially around the nose (grade 1). Cataract and periorbital edema and discharge of the left eye were observed 4 months after radiation therapy. In March 2018, the patient noticed bleeding from the mouth, and an oral examination revealed a defect of the right upper gum with exposure of a necrotic maxilla. These findings were within the irradiation field, and we made the diagnosis of periodontal disease.

The patient remained recurrence-free until the 18-month follow-up visit after treatment completion ([Fig 5](#fig5){ref-type="fig"}). Eventually, in July 2018, subcutaneous induration measuring up to 26 mm appeared near the right corner of the mouth, which had received a dose of approximately 60 Gy during the previous radiation therapy. The patient stopped visiting our hospital after August 2018; therefore, the progress of the tumor thereafter is unknown.Figure 5Clinical photograph of the patient after treatment (January 2018).

Discussion {#sec3}
==========

The treatment of first choice for sweat gland carcinomas is surgery, but few reports exist about definitive radiation therapy for these cancers. A summary of cases of sweat gland carcinoma treated with definitive radiation therapy in the last 3 decades is shown in [Table 1](#tbl1){ref-type="table"}. Herein, we defined sweat gland carcinoma as a cutaneous tumor, as mentioned in a review of malignant sweat gland tumors by Ahn et al.[@bib12] Among the 8 cases listed in [Table 1](#tbl1){ref-type="table"}, 4 cases (50%) remained recurrence-free until the end of the follow-up period. Definitive radiation therapy for sweat gland carcinoma can also be deemed effective for the local control in some cases. Therefore, we believe that definitive radiation therapy for sweat gland carcinoma is a potentially valid treatment alternative for cases in which surgery is expected to be difficult.Table 1Summary of some cases of sweat gland carcinoma treated by definitive radiation therapy (except adjuvant RT) in the last 3 decadesStudy first authorReporting yearAgeSexSiteHistologic typeMethodDose (Gy)Number of fractionsChemotherapyFollow-up (y)OutcomeAuw-Haedrich[@bib5]200187MRight eyelid and right orbital cavity (primary tumor)Signet ring cell carcinoma of the eccrine sweat glandNot listed56Not listedNone1.2NEDStein[@bib6]200376FRight nasal dorsum (primary tumor)Microcystic adnexal carcinomaExternal beam RT58Not listedNone0.5LRYamashita[@bib7]200861MLymph nodes from the left inguinal and internal iliac to the abdominal paraaortic regionEccrine porocarcinoma6-MV photons50.428CDDP+5-FU0.5NEDMotta[@bib8]200971FScalp (Local recurrence after surgery and adjuvant RT)Eccrine mucinous adenocarcinomaHelical tomotherapy5020None1NEDLalya[@bib9]201168FLeft parotid area (local recurrence after surgery)Clear cell hidradenocarcinomaExternal beam RT66[∗](#tbl1fnlowast){ref-type="table-fn"}133None1.25NEDPugh[@bib10]201253Fa. Upper lip (primary tumor)\
b. Upper lip (local recurrence after RT)Microcystic adnexal carcinomaa. 9-MeV electron, followed by low-dose iridium-192 brachytherapy\
b. 9-MeV electrona. 63.6[†](#tbl1fndagger){ref-type="table-fn"}2\
b. 64a. 26(electron)\
b. 32Nonea. 4\
b. 1.25a. LR\
b. NEDMiller[@bib11]201532MBilateral axillary lymph nodesApocrine hidradenocarcinomaExternal beam RT50.428CBDCA+PTXNot listedPD[‡](#tbl1fnddagger){ref-type="table-fn"}3Present Report201979FFace, mainly in both cheeks and around the nose (primary tumor)Syringomatous carcinoma6-MV photons, IMRT6030None2LR[^1][^2][^3][^4]

In our case report, IMRT was used as the radiotherapeutic modality to treat syringomatous carcinoma. IMRT has the ability to deliver high doses of radiation to the tumor target with very high precision while minimizing the dose received by the surrounding normal tissues.[@bib13] For the case of squamous cell carcinoma of the head and neck, randomized studies have demonstrated that IMRT is associated with a reduced incidence of side effects (particularly xerostomia) compared with 3-dimensional conformal radiation therapy (CRT).[@bib14] Some previous case reports exist[@bib8], [@bib15] of facial skin cancer treated with IMRT, but to the best of our knowledge, there are no other reports on the use of IMRT to treat syringomatous carcinoma.

To date, there is no evidence that in cases of facial skin cancer, IMRT is associated with a reduced incidence of side effects compared with 3-dimensional CRT. However, we hypothesize that IMRT may also be useful to treat sweat gland carcinomas of the face near the OAR in terms of a reduced incidence of adverse events compared with 3-dimensional CRT. This is because facial skin cancer is sometimes located near the OAR, and during radiation therapy, the doses delivered to the OAR may cause adverse events. For example, Auw-Haedrich et al[@bib5] reported on a case of signet ring cell carcinoma of the eccrine sweat glands located at the right eyelid and right orbital cavity that was treated with definitive radiation therapy. The patient became blind in the right eye after radiation therapy. If our case had been treated with 3-dimensional CRT, the doses delivered to the right lens might have exceeded the dose constraint, and adverse events such as right cataract might have occurred. Thus, in cases of syringomatous carcinoma that affect wide areas of the face, we believe that IMRT may be particularly useful.

In this case report, the tumor recurred within 2 years of treatment. The optimal radiation dose for definitive radiation therapy of sweat gland carcinomas is still unknown. However, as shown in [Table 1](#tbl1){ref-type="table"}, some cases treated with a total dose of \<65 Gy developed local recurrence. In addition, Pugh et al[@bib10] reported on the optimal dose for gross microcystic adnexal adenocarcinoma, which is one of the sweat gland carcinomas. The researchers extrapolated the data reported for squamous cell carcinoma of the head and neck reported in literature, and proposed a dose of 66 Gy to 70 Gy with standard fractionation or a biologically equivalent regimen. When taking all available evidence into consideration, a dose of 60 Gy for definitive radiation therapy of syringomatous carcinoma may be insufficient, and a dose of 66 Gy to 70 Gy with standard fractionation may yield better outcomes.

Conclusions {#sec4}
===========

We report on the case of a 79-year-old female patient with syringomatous carcinoma of the face, who was treated with IMRT, which resulted in temporary palliation. IMRT may be considered as a valid treatment alternative for cases of syringomatous carcinoma in which surgery is difficult to perform, and IMRT may minimize the risk of adverse events.

Sources of support: This work had no specific funding.

Conflicts of interest: The authors have no conflicts of interest to disclose.

[^1]: *Abbreviations:* 5-FU = 5-fluorouracil; CBDCA = carboplatin; CDDP = cisplatin; IMRT = intensity modulated radiation therapy; LR = local recurrence; NED = no evidence of disease; PD = progressive disease; PTX = paclitaxel; RT = radiation therapy.

[^2]: 66 Gy to the tumor bed, and 50 Gy to the regional lymphatic chains.

[^3]: 41.6 Gy(electron) + 22 Gy (brachytherapy).

[^4]: Clear response at the irradiation site, but multiple metastasis occurred.
